Our law firm is currently handling lawsuits on behalf of individuals who have taken Ukoniq to treat two specific types of lymphoma. Ukoniq may cause an increased rate of death in patients with cancer.
Marginal zone lymphoma (MZL) and follicular lymphoma (FL) originate in white blood cells called lymphocytes. Ukoniq is prescribed for adult patients with (i) MZL when the disease has returned or failed to respond to one previous treatment regimen and (ii) FL when the disease has retuned or failed to respond to three prior treatment regimens. Ukoniq belongs to a class of medications known as PI₃ kinase inhibitors, which prevents an abnormal protein from triggering the production of cancer cells.
The U.S. Food and Drug Administration (FDA) is investigating an increased risk of death in patients taking Ukoniq. The FDA warning, issued on February 3, 2022, states that the agency is evaluating the side effects of Ukoniq and conducting a risk-benefit analysis of the medication in light of the results of clinical trials.
Ukoniq has been linked with an increased rate of infection and may potentially result in death.
The Lake Law Firm was founded by Edward J. Lake, Esq., a personal injury lawyer for over 25 years. Our dedicated team of attorneys is committed to seeking justice on behalf of those who have suffered injury or death due to the negligence of others. Our experienced attorneys handle many different types of pharmaceutical drugs, medical devices, and other defective products. The lawyers in our firm have helped collect millions of dollars for their clients. The Lake Law Firm will advocate for you and your rights. Please contact us for a free confidential case evaluation at (888) 274-0139 or submit an inquiry on this page.
The FDA announced that it is considering the risks and benefits of Ukoniq after a clinical trial that found an increased risk of death in patients taking Ukoniq to treat a cancer that is similar to the types of cancer for which Ukoniq is FDA approved. As a result of the clinical trial known as UNITY, the FDA intends to hold a public meeting to review the findings of the trial. The FDA has also halted the enrollment of new patients in other clinical trials involving Ukoniq while the UNITY results are evaluated.
The UNITY trial explored data in patients with chronic lymphocytic leukemia. The results demonstrated an increased risk of death and other serious side effects in patients who took Ukoniq in combination with a monoclonal antibody. The FDA believes that the results of this trial may have implications for patients taking Ukoniq to treat MZL and FL.